Stay updated on Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial
Sign up to get notified when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.

Latest updates to the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision label updated to v3.5.0 (from v3.4.3).SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedRevision label updated to v3.4.3. The previous label v3.4.2 has been removed.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page now displays Revision: v3.4.2, replacing Revision: v3.4.1. This appears to be a minor maintenance update and does not change study information; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check58 days agoChange DetectedSite revision updated from v3.4.0 to v3.4.1. This change does not affect any study details, eligibility criteria, results, or timeframes.SummaryDifference0.0%

- Check72 days agoChange DetectedGlossary display added; metadata labels updated to show Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, replacing the previous QC label, FEAR Act data label, and Revision: v3.3.4.SummaryDifference0.2%

- Check79 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4; no core study information or user-facing elements were altered.SummaryDifference0.0%

Stay in the know with updates to Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.